ESTRO 2024 - Abstract Book

S1384

Clinical - Head & neck

ESTRO 2024

Brennan P, Waterboer T, Johansson M. Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium. Ann Oncol. 2019 Aug 1;30(8):1335-1343. doi: 10.1093/annonc/mdz138. PMID: 31185496.

(3) Busch CJ, Hoffmann AS, Viarisio D, Becker BT, Rieckmann T, Betz C, Bender N, Schroeder L, Hussein Y, Petersen E, Jagodzinski A, Schäfer I, Burandt E, Lang Kuhs K, Pawlita M, Waterboer T, Brenner N. Detection of stage I HPV-driven oropharyngeal cancer in asymptomatic individuals in the Hamburg City Health Study using HPV16 E6 serology - A proof-of-concept study. EClinicalMedicine. 2022 Sep 17;53:101659. doi: 10.1016/j.eclinm.2022.101659. eCollection 2022 Nov. PMID: 36147627

2228

Digital Poster

Lymphovascular invasion as prognostic factor in locally advanced oral tongue cancer

Parveen Ahlawat, Sarthak Tandon, Sandeep Purohit, Akash R Bellige, Shaifali Mahajan, Gerim Prasai, Sauharda Lohani, Aslam Najeem, Apoorva Nayak, Munish Gairola

Rajiv Gandhi Cancer Institute and Research Centre, Radiation Oncology, New Delhi, India

Purpose/Objective:

Various pathological prognostic factors such as pathological T stage (pT stage), pathological N stage (pN stage), extranodal extension (ENE), bony involvement, positive or close resection margin, perineural invasion (PNI), extranodal extension (ENE), depth of invasion (DOI), and worst pattern of invasion (WPOI) have been identified for oral tongue cancer (OTC). Invasion of the lymphatic vessels is the first step in the development of metastasis. Lymphatic invasion (LVI) as a prognostic factors for locally advanced oral cancer has been evaluated but most studies included all subsites of oral cavity. Oral tongue may behave differently than other subsites. This research compares the patients and disease-related characteristics, and disease outcome between patients with LVI and without LVI in a large cohort of patients with OTC subsite.

Material/Methods:

A retrospective chart review was done for patients with resectable OTC who underwent upfront surgical resection between 2008 and 2021. For the purpose of analysis restaging of primary tumour and nodal disease was done with AJCC 8th edition. Entire patient population was divided into two cohorts, patients with LVI and without LVI. Baseline characteristics were compared between the two groups. The outcome endpoints for the study selected were locoregional control (LRC) and overall survival (OS). LRC was defined from the date of diagnosis to the date of local and/or regional recurrence or death due to any cause. OS was defined from the date of diagnosis to the date of death due to any cause.

Results: